ArriVent is a pre-revenue, cash-burning biotech whose value rides on one pipeline asset, firmonertinib, with analyst targets implying 50.9% upside against 15.0% downside. Weak business quality and repeated earnings misses cap conviction, so any position is speculative.
Thesis pillars
- Single Asset Pipeline Concentration↓Deteriorating
- Persistent Losses Earnings Misses→Stable
- Analyst Upside Favorable Asymmetry→Stable
- +2 more pillars — see the Why tab for full reasoning
Pillars as of Nov 1, 2026, based on the 10-K filed Mar 5, 2026
ArriVent BioPharma, Inc. (AVBP) Stock Analysis
Falling Knife setup · Inst Constrain edge
Healthcare · Biotechnology
Sell if holding. Engine safety override at $13.49: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 4.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Elevated put/call ratio: 12.00; Below-average business quality.
ArriVent BioPharma is a clinical-stage biopharmaceutical company developing firmonertinib, an EGFR mutant-selective tyrosine kinase inhibitor for non-small cell lung cancer (NSCLC), which it licensed from Shanghai Allist Pharmaceuticals for all territories outside greater China.... Read more
Sell if holding. Engine safety override at $13.49: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 4.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Elevated put/call ratio: 12.00; Below-average business quality. Chart setup: Death cross, below all MAs, RSI 38, MACD bearish. Score 5.3/10, moderate confidence.
Passes 6/9 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum and death cross (50MA < 200MA). Suitability: speculative.
About ArriVent BioPharma, Inc.
About ArriVent BioPharma, Inc.
ArriVent BioPharma's lead asset, firmonertinib, is in two pivotal Phase 3 trials for non-small cell lung cancer: FURVENT, which enrolled 398 patients with EGFR exon 20 insertion mutations and expects topline data in mid-2026, and ALPACCA, targeting PACC mutations, which dosed its first patient in December 2025. ArriVent licensed firmonertinib from Shanghai Allist Pharmaceuticals in 2021 for all territories outside greater China, and the FDA has granted the drug Breakthrough Therapy and Orphan Drug designations.
ArriVent has never generated product revenue and its commercial revenue, if any, will initially come from firmonertinib sales, not expected for years even if approved; the company posted a $166.3 million net loss in 2025 against a $404.6 million accumulated deficit. Under its license agreements, ArriVent owes Allist up to $765.0 million and Lepu Biopharma up to $1.17 billion in development, regulatory, and sales milestone payments, plus tiered net-sales royalties to both partners, and up to $98.0 million in milestones to Aarvik Therapeutics under a separate antibody-drug-conjugate collaboration. Firmonertinib, ARR-217, and preclinical candidate ARR-002 are all manufactured by Chinese third parties for clinical development, and ArriVent expects to rely on the same manufacturers for future commercial supply. Beyond its lead asset, the company is building an ADC pipeline through Aarvik's conjugation platform and a 2024 collaboration with Jiangsu Alphamab Biopharmaceuticals.
Show full overview
ArriVent's entire clinical and prospective commercial supply chain runs through Chinese contract manufacturers: the 10-K states that the company relies on Chinese third parties for the manufacture of firmonertinib, ARR-217, and ARR-002, and expects to continue relying on third parties for the foreseeable future, with no in-house manufacturing capacity disclosed. That concentration compounds a separate structural dependency: ArriVent's risk factor summary states that the company currently depends significantly on the success of firmonertinib alone, with ARR-217 still in Phase 1 and no other clinical-stage asset positioned to offset a setback. A trial delay, an FDA objection to non-U.S. patient data (several firmonertinib and ARR-217 trials run in China), or a Chinese manufacturing disruption would each hit the same single value driver.
See also: Healthcare · Biotechnology
From ArriVent BioPharma, Inc.'s most recent 10-K filing, extracted July 6, 2026.
Recent developments
updated Nov 2, 2026Recent Developments — ArriVent BioPharma, Inc.
Latest news
- NEWS ArriVent BioPharm Announces License Agreement With Laurus Labs; Laurus Labs To Obtain Licenses For Two MUTTA ADC Molecul — benzinga Nov 2, 2026 positive
- NEWS Guggenheim Raises ArriVent BioPharma Price Target to $30.00 — fiscal.ai Oct 28, 2026 positive
- NEWS Guggenheim Maintains Buy on ArriVent BioPharma, Raises Price Target to $30 — benzinga Oct 27, 2026 positive
- NEWS 12 Health Care Stocks Moving In Monday's Intraday Session — benzinga Oct 26, 2026 neutral
- NEWS Why Surgery Partners Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket — benzinga Oct 26, 2026 positive
Latest item Nov 2, 2026 · Generated 2026-11-05T11:54:11Z.
Upcoming dated catalysts
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinefirmonertinib10-K Item 1A: 'We currently depend significantly on the success of firmonertinib.'
- HIGHSupplierChinese third-party manufacturers10-K Item 1A: 'We currently rely on Chinese third parties for the manufacture of firmonertinib, ARR-217, and ARR-002 for clinical development'
- HIGHcounterpartyexclusive licensors10-K Item 1A: 'We heavily rely on our exclusive licenses with our partners to provide us with intellectual property rights to develop and commercialize our product candidates.'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Editorial policy
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. People who build TrendMatrix, or entities they control, may hold positions, long or short, in securities it covers, and may trade them at any time. Positions are not disclosed individually. Verdicts are generated by an automated model applied by the same rules to every covered stock, and are not adjusted for any position held by the people who build TrendMatrix. We do not accept payment from issuers for coverage.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
Rating Breakdown
3 floor-breakers·2 ceiling hits
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Price action weak — below key moving averages, no momentum carry. Needs a base before trend-continuation setups apply.static
No near-term catalyst priced in. Thesis progression will come from fundamentals grinding, not event reaction.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $13.49: a dimension score below its floor triggers a hard block regardless of the otherwise-positive setup — overall score 5.3/10 and A.R:R 4.4:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 15%; Elevated put/call ratio: 12.00; Below-average business quality. Chart setup: Death cross, below all MAs, RSI 38, MACD bearish. Prior stop was $12.55. Score 5.3/10, moderate confidence.
Analyst target: $22.45 (+66.4% upside). Prior stop was $12.55. Stop-loss: $12.55.
Concentration risk — Pipeline: firmonertinib; Concentration risk — Supplier: Chinese third-party manufacturers; Quality below floor (1.6 < 4.0).
ArriVent BioPharma, Inc. trades at a P/E of N/A (forward -3.6). TrendMatrix value score: 9.0/10. Verdict: Sell.
18 analysts rate AVBP, with a consensus score of 4.3/5. 10 analysts publish price targets averaging $26.
What does ArriVent BioPharma, Inc. do?ArriVent BioPharma is a clinical-stage biopharmaceutical company developing firmonertinib, an EGFR mutant-selective...
ArriVent BioPharma is a clinical-stage biopharmaceutical company developing firmonertinib, an EGFR mutant-selective tyrosine kinase inhibitor for non-small cell lung cancer (NSCLC), which it licensed from Shanghai Allist Pharmaceuticals for all territories outside greater China. The company is running two pivotal Phase 3 trials of firmonertinib (FURVENT for exon 20 insertion mutations, ALPACCA for PACC mutations) and advancing ARR-217, an antibody-drug conjugate licensed from Lepu Biopharma, currently in Phase 1. ArriVent has no approved products or product revenue, reporting a $166.3 million